Tsumura & Co
TSE:4540

Watchlist Manager
Tsumura & Co Logo
Tsumura & Co
TSE:4540
Watchlist
Price: 4 125 JPY 1.18% Market Closed
Market Cap: 316.6B JPY

Relative Value

The Relative Value of one Tsumura & Co stock under the Base Case scenario is 4 885.41 JPY. Compared to the current market price of 4 125 JPY, Tsumura & Co is Undervalued by 16%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
4 885.41 JPY
Undervaluation 16%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
60
vs Industry
52
Median 3Y
1.5
Median 5Y
1.8
Industry
2.6
Forward
1.6
vs History
77
vs Industry
35
Median 3Y
12.3
Median 5Y
12.8
Industry
21.4
Forward
11.3
vs History
61
vs Industry
34
Median 3Y
16.1
Median 5Y
12.8
Industry
16.4
vs History
39
vs Industry
10
Median 3Y
-19.8
Median 5Y
8.2
Industry
22.8
vs History
44
vs Industry
57
Median 3Y
0.9
Median 5Y
1
Industry
2.2
vs History
31
vs Industry
52
Median 3Y
1.6
Median 5Y
1.7
Industry
2.9
Forward
1.8
vs History
30
vs Industry
49
Median 3Y
3.3
Median 5Y
3.4
Industry
5.5
vs History
46
vs Industry
39
Median 3Y
6.5
Median 5Y
7
Industry
13
Forward
7.1
vs History
69
vs Industry
37
Median 3Y
9.4
Median 5Y
10
Industry
16.5
vs History
44
vs Industry
35
Median 3Y
15.6
Median 5Y
12.3
Industry
15.6
vs History
vs Industry
9
Median 3Y
-20
Median 5Y
20.6
Industry
18.7
vs History
50
vs Industry
60
Median 3Y
0.7
Median 5Y
0.8
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Tsumura & Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Tsumura & Co
TSE:4540
306.6B JPY 1.7 11.2 7.1 9.4
US
Eli Lilly and Co
NYSE:LLY
978.2B USD 16.5 53.1 35.7 38.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.6B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
257.9B CHF 4.2 27.4 11.7 13.6
UK
AstraZeneca PLC
LSE:AZN
206.8B GBP 4.8 29.6 108.2 158.3
US
Merck & Co Inc
NYSE:MRK
265B USD 4.1 13.9 9.9 11.7
CH
Novartis AG
SIX:NOVN
207.5B CHF 4.7 18.2 11.6 14.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.8 14.7 10.3 12
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
142.7B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
JP
Tsumura & Co
TSE:4540
Average P/E: 22.5
11.2
-3%
N/A
US
Eli Lilly and Co
NYSE:LLY
53.1
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.4
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.6
37%
0.8
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
CH
Novartis AG
SIX:NOVN
18.2
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
3%
4.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Tsumura & Co
TSE:4540
Average EV/EBITDA: 400.2
7.1
2%
3.6
US
Eli Lilly and Co
NYSE:LLY
35.7
34%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
CH
Novartis AG
SIX:NOVN
11.6
6%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Tsumura & Co
TSE:4540
Average EV/EBIT: 1 712.8
9.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.6
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
CH
Novartis AG
SIX:NOVN
14.9
12%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
12
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4